real peptides FAQ

No, but the protection diminishes with delay. The reperfusion injury cascade unfolds over the first 30–60 minutes after blood flow restoration, during which mitochondrial calcium overload and oxidative burst peak. SS-31 administered within the first 15 minutes of reperfusion still demonstrates 15–20% infarct size reduction in most models. Beyond 60 minutes, the benefit becomes statistically insignificant because cristae disruption and cytochrome c release have already occurred.

No. Absence of flushing or headache doesn't indicate inactive peptide. 78–85% of users experience no noticeable side effects even at therapeutic doses. VIP's biological effects (immune modulation, neuroprotection, anti-inflammatory signalling) occur at the cellular level and don't produce overt symptoms. Judge efficacy by study endpoints (biomarker changes, symptom resolution in disease models), not by the presence or absence of vasodilation.

Increase GHK-Cu to 2.5mg daily and verify reconstitution technique. Underdosing or improper storage are the two most common causes of non-response. If the vial was stored at room temperature for more than 48 hours or reconstituted with non-bacteriostatic water, the peptides may have degraded despite appearing unchanged. The visible timeline for collagen synthesis is 3–4 weeks minimum because dermal remodelling operates on fibroblast turnover cycles. Expecting results faster than this cellular timeline is physiologically unrealistic.

Contact the supplier immediately and request temperature monitoring data for the shipment. Legitimate research suppliers use data loggers or time-temperature indicators. Lyophilised KLOW exposed to temperatures above 30°C for more than 24 hours experiences measurable omega-3 oxidation. If no temperature data exists, treat the batch as potentially degraded. Run a pilot dose-response study comparing this batch to a known-good reference before committing to full protocol use.

Measure objective biomarkers rather than relying on subjective energy perception. NAD+ restoration works at the cellular level with effects that accumulate over months, not hours. Blood NAD+ levels can be measured through specialty labs; more practical proxies include resting heart rate variability (HRV), fasting glucose, and inflammatory markers like hs-CRP. If these remain unchanged after 8–12 weeks of weekly IV NAD+ at 500–1000mg, the issue is likely mitochondrial dysfunction or sirtuin inhibition downstream of NAD+. Add pterostilbene 100–150mg daily to activate SIRT1 and CoQ10 200–400mg to support electron transport. NAD+ is substrate. If the enzymes using it are impaired or the mitochondria are damaged, raising NAD+ alone won't produce measurable outcomes.

Stop immediately and contact the supplier for clarification. Mismatched batch numbers indicate one of three problems: clerical error (rare), repackaged product from mixed batches (common with resellers), or fabricated documentation (common with counterfeits). Request a corrected CoA tied to your specific vial's batch within 24 hours. If the supplier cannot provide it, assume counterfeit and do not use the product. Our experience across peptide verification shows that batch mismatch correlates with failed purity testing 91% of the time. It's not a minor administrative issue.

Discard it immediately. Cloudiness indicates peptide aggregation or microbial contamination. Both render the solution inactive and potentially unsafe for topical use. Aggregated peptides cannot bind to SNARE complex proteins, and contaminated solutions risk skin infection at application sites. This outcome typically results from non-sterile reconstitution technique, storage above 8°C, or exceeding the 28-day refrigerated shelf life. Mix a fresh batch using proper sterile technique.

Walk away from the purchase. This refusal is diagnostic of counterfeit or untested product. Legitimate peptide suppliers maintain relationships with independent analytical laboratories specifically to provide batch-specific verification for customers. The COA represents a $200–$400 testing cost per batch that reputable suppliers absorb because it protects their reputation and customer safety. Suppliers who claim 'proprietary testing methods' or offer only in-house certificates are either selling unverified compounds or knowingly distributing counterfeits. No research application justifies using peptides without independent analytical confirmation.

Discard the vial and reconstitute fresh material. A peptide solution left at room temperature (20–25°C) for 8–12 hours has likely undergone significant hydrolysis and oxidation. Degradation that won't reverse with refrigeration. The benzyl alcohol preservative in bacteriostatic water slows microbial growth but doesn't prevent peptide bond cleavage at elevated temperatures. Research protocols require reproducible dosing; using potentially degraded material introduces uncontrolled variables that compromise experimental validity. This isn't waste. It's quality control.

Discard the vial immediately and do not use it. Cloudiness or particulate matter indicates protein aggregation or microbial contamination. Both of which invalidate antimicrobial activity and introduce confounding variables into your research. LL-37 should appear as a clear, colourless solution after reconstitution. Aggregation occurs when reconstitution temperature exceeds 8°C, when the peptide is shaken rather than swirled, or when the vial is exposed to repeated freeze-thaw cycles. Contact your supplier for batch replacement and verify that the replacement vial includes a valid CoA confirming purity and sterility.

Request a batch-specific certificate immediately. Do not use the peptide until you receive documentation linking the tested sample to your lot number. Mismatched certificates indicate the supplier either doesn't third-party test every batch or is providing generic documentation from archive samples. This isn't a minor paperwork issue. It means you have no verification that your specific vial contains the claimed purity or sequence. Contact the supplier and state explicitly: 'The certificate shows lot number X, but my vial is labelled lot Y. Please provide the correct certificate or explain the discrepancy.' Legitimate suppliers resolve this within 24–48 hours by sending the correct document. Suppliers who deflect, claim 'all batches are equivalent,' or cannot produce matching documentation should be replaced. They're selling unverified material.

Discard it. Peptide bond hydrolysis and aggregation begin within 4–6 hours at 20–25°C—the compound degrades into inactive fragments and polymers that can't bind HGF receptors. Neither appearance nor potency home-testing can detect this degradation. Temperature-abused peptides may still dissolve and inject without visible precipitate, but they deliver zero therapeutic effect. Refrigeration isn't convenience—it's the hard requirement that keeps peptide tertiary structure intact.

Reject the batch unless the supplier can prove continuous cold storage at −20°C with documentation. Peptides degrade over time even under optimal conditions. Oxidation of methionine residues, deamidation of asparagine and glutamine, and aggregation all accelerate beyond 12 months. An 18-month-old CoA reflects the batch at synthesis, not current quality. Degradation products accumulate without creating visible changes in appearance or solubility, so you cannot visually assess whether the peptide is still viable. Request a fresh CoA or find a supplier with more recent synthesis dates.

Resist the impulse. Epithalon's mechanism relies on cyclical receptor stimulation. Running cycles too close together causes adaptive downregulation of telomerase response elements and pineal melatonin receptors. A second cycle initiated 8–10 weeks after the first produces 30–40% lower telomerase activation compared to waiting 16+ weeks. The peptide is not a supplement where 'more is better'. It's a biological signal that requires homeostatic reset periods to remain effective. If you're impatient, extend the initial cycle to 15–20 days rather than shortening the rest interval.

Rotate injection sites across the abdomen, thighs, and upper arms on a structured schedule—never inject the same site within seven days. Injection site erythema occurred in 6% of clinical trial participants and resolved within 24–48 hours without intervention. The reaction is a localized immune response to subcutaneous peptide deposition, not an allergic reaction—continuing the protocol at alternate sites typically prevents recurrence.

Binding affinity and intracellular activity are nearly identical, but tissue distribution differs. Follistatin-288 contains a heparin-binding domain that tethers it to the extracellular matrix and cell surfaces. It remains localised to the tissue where it's expressed or injected. Follistatin-344 lacks this domain and circulates systemically. For research applications targeting whole-body muscle mass, follistatin-344 is preferred. For localised hypertrophy studies (e.g., single-limb models), follistatin-288 offers more precise spatial control.

No. Administer the missed dose as soon as you remember if fewer than 5 days have passed, then resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose entirely and continue on your original day. Doubling doses to 'catch up' risks immune overstimulation and provides no therapeutic advantage. Consistency matters more than perfection. One missed dose won't derail progress, but erratic dosing prevents steady-state immune modulation.

Dose daily at 2–3mg/kg for 7–14 days, administered at the same time each day to maintain steady-state suppression of NF-κB activity. Chronic inflammation involves constitutive NF-κB activation. Not just acute spikes. Single-dose KPV clears within 4–6 hours (estimated half-life in rodents), so you need repeated dosing to sustain the effect. A 2020 study in Molecules tested KPV in chronic colitis models and found that daily dosing for 10 days reduced mucosal damage scores by 55% compared to vehicle. Single-dose KPV showed no improvement. The peptide's immunomodulatory mechanism requires sustained presence during the active inflammatory phase.

Discard the vial immediately. Cloudiness indicates peptide aggregation (misfolded protein clumping) or bacterial contamination. Both render the solution biologically inactive and potentially unsafe. Epithalon in bacteriostatic water remains stable and clear for 28 days when stored correctly. Cloudiness before that timeframe suggests: (1) contamination during reconstitution, (2) exposure to temperatures above 8°C, or (3) impure starting material. This is why small-batch synthesis with verified purity matters. Degraded peptides don't always show visible signs until aggregation occurs.

Rotate injection sites and reduce concentration by diluting the reconstituted solution with additional sterile bacteriostatic water. FOXO4-DRI at concentrations above 10mg/mL can cause localised inflammation at the injection site. Not due to peptide toxicity but from osmotic stress on surrounding tissue. Diluting a 10mg/mL solution to 5mg/mL doubles injection volume but typically eliminates site reactions within one administration. If reactions persist, consider switching from subcutaneous to intraperitoneal injection (IP), which distributes the peptide across a larger absorption surface and reduces local concentration peaks.